{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:51:54Z","timestamp":1780498314930,"version":"3.54.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848050005"],"award-info":[{"award-number":["848050005"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40264-020-00946-z","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T10:02:39Z","timestamp":1590400959000},"page":"917-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2303-6199","authenticated-orcid":false,"given":"Jette A.","family":"van Lint","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8267-1259","authenticated-orcid":false,"given":"Naomi T.","family":"Jessurun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske C. F.","family":"Hebing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hoentjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander W.","family":"Tas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald E.","family":"Vonkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn B. A.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Sobels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6035-2863","authenticated-orcid":false,"given":"Phyllis I.","family":"Spuls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene P.","family":"van Puijenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8560-9514","authenticated-orcid":false,"given":"Bart J. F.","family":"van den Bemt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,25]]},"reference":[{"key":"946_CR1","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s10067-017-3712-8","volume":"36","author":"EG Favalli","year":"2017","unstructured":"Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, et al. Real-life 10-year retention rate of first line anti-TNF drug for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Clin Rheumatol. 2017;36:1747\u201355.","journal-title":"Clin Rheumatol"},{"key":"946_CR2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s40264-018-0684-9","volume":"41","author":"Y Ingrasciotta","year":"2018","unstructured":"Ingrasciotta Y, Cutronea PM, Marcian\u00f2 I, Giezen T, Atzeni F, Trifir\u00f2 G. Safety of biologics, including biosimilars: perspectives on current status and future direction. Drug Saf. 2018;41:1013\u201322.","journal-title":"Drug Saf"},{"key":"946_CR3","first-page":"29","volume":"36","author":"L Leon","year":"2018","unstructured":"Leon L, Gomez A, Vadillo C, Pato E, Rodriguez-Rodriguez L, Jover JA, et al. Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clin Exp Rheumatol. 2018;36:29\u201335.","journal-title":"Clin Exp Rheumatol"},{"key":"946_CR4","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1136\/annrheumdis-2011-200838","volume":"71","author":"R Sakai","year":"2012","unstructured":"Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, et al. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis. 2012;71:1820\u20136.","journal-title":"Ann Rheum Dis"},{"key":"946_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/rheumatology\/keq300","volume":"50","author":"L G\u00e4wert","year":"2011","unstructured":"G\u00e4wert L, Hierse F, Zink A, Strangfeld A. How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician- and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologic register. Rheumatology. 2011;50:152\u201360.","journal-title":"Rheumatology"},{"issue":"1","key":"946_CR6","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1517\/14740338.2014.947260","volume":"13","author":"C Leporini","year":"2014","unstructured":"Leporini C, De Sarro G, Russo E. Adherence to therapy and adverse drug reactions: is there a link? Expert Opin Drug Saf. 2014;13(1):S41\u201355.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"946_CR7","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/rheumatology\/kez412","volume":"59","author":"LJ Kosse","year":"2020","unstructured":"Kosse LJ, Jessurun NT, Hebing RCF, Huiskes VJB, Spijkers KM, van den Bemt BJF, et al. Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. Rheumatology. 2020;59(6):1253\u201361. https:\/\/doi.org\/10.1093\/rheumatology\/kez412.","journal-title":"Rheumatology"},{"issue":"2","key":"946_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"key":"946_CR9","first-page":"A9385","volume":"159","author":"AA Den Broeder","year":"2015","unstructured":"Den Broeder AA, Schers HJ. Serious infection due to biologicals: risk only mildly elevated in patients with rheumatoid arthritis. Ned Tijdschr Geneesk. 2015;159:A9385 (Dutch).","journal-title":"Ned Tijdschr Geneesk"},{"issue":"3","key":"946_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/joim.12635","volume":"282","author":"J Helby","year":"2017","unstructured":"Helby J, Nordestgaard BG, Benfield T, Bojesen SE. Asthma, other atopic conditions and risk of infections in 105,519 general population never and ever smokers. J Intern Med. 2017;282(3):254\u201367.","journal-title":"J Intern Med"},{"issue":"5","key":"946_CR11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.medmal.2012.02.003","volume":"42","author":"J Obert","year":"2012","unstructured":"Obert J, Burgel PR. Pneumococcal infections: association with asthma and COPD. Med Mal Infect. 2012;42(5):272\u20137.","journal-title":"Med Mal Infect"},{"issue":"3","key":"946_CR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1037\/0021-843X.97.3.346","volume":"97","author":"D Watson","year":"1988","unstructured":"Watson D, Clark LA, Carey G. Positive and negative affectivity and their relation to anxiety and depressive disorders. J Abnorm Psychol. 1988;97(3):346\u201353.","journal-title":"J Abnorm Psychol"},{"key":"946_CR13","first-page":"247","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: Harcourt Book Publishers; 2000. p. 247.","edition":"4"},{"key":"946_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12264","author":"CC Mok","year":"2014","unstructured":"Mok CC, Chan KY, Lee KL, Tam LS, Lee KW. Factors associated with withdrawal of the anti-TNFa biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry. Int J Rheum Dis. 2014. https:\/\/doi.org\/10.1111\/1756-185X.12264.","journal-title":"Int J Rheum Dis"},{"key":"946_CR15","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s10067-015-2929-7","volume":"34","author":"BP Faf\u00e1","year":"2015","unstructured":"Faf\u00e1 BP, Louzada-Junior P, Titton DC, Zandonade E, Ranza R, Laurindo I, et al. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL. Clin Rheumatol. 2015;34:921\u20137.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"946_CR16","doi-asserted-by":"publisher","first-page":"e30275","DOI":"10.1371\/journal.pone.0030275","volume":"7","author":"KJ Aaltonen","year":"2012","unstructured":"Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstr\u00f6m DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012;7(1):e30275. https:\/\/doi.org\/10.1371\/journal.pone.0030275.","journal-title":"PLoS One"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00946-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-00946-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00946-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T23:34:02Z","timestamp":1621899242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-00946-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,25]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["946"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-00946-z","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,25]]},"assertion":[{"value":"25 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The <i>Dutch Biologic Monitor<\/i> work was supported by the Netherlands Organisation for Health Research and Development (ZonMw) [grant number 848050005]. No funding was received for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JA van Lint, NT Jessurun, RCF Hebing, SW Tas, HE Vonkeman, A Sobels, EP van Puijenbroek, MT Nurmohamed and BJF van den Bemt declare that they have no conflicts of interest. PI Spuls reports unpaid consultancies for Sanofi and Abbvie in the past, a departmental independent research grant for the TREAT NL registry from Leopharma, financial compensation from pharmaceutical industries to her department\/hospital for involvement in performing clinical trials and she is chief investigator in the Netherlands national systemic and phototherapy atopic eczema registry (TREAT NL). MBA van Doorn reports grants from Novartis; consulting fees or honorarium from Leopharma, Novartis, Abbvie, BMS, Celgene, Janssen-Cilag, Lily, MSD, Pfizer and Sanofi-Genzyme; support for travel, manuscript preparation or other purposes from Sanofi-Genzyme, Novartis and Pfizer; payment for lectures from Leopharma, Novartis, Janssen-Cilag and Pfizer, all outside the submitted work. F Hoentjen reports received grants, consulting fees or honorarium and payment for lectures, all outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethical approval was waived for the Dutch Medical Research Involving Human Subjects Act (WMO) by the Medical Research Ethical Committee of Brabant, the Netherlands (file number: NW2016-66). The <i>Dutch Biologic Monitor<\/i> was approved by the medical ethics committees of the participating hospitals. All participants received information about the <i>Dutch Biologic Monitor<\/i> prior to participation and signed a digital informed consent form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The dataset analysed during the current study is available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}